secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aura Biosciences, Inc. (AURA)
CIK:        0001501796
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0000950170-23-062074
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aura Biosciences raises $99M in public offering; Q3 net loss $18.5M
-------------------------------------------------------------------

- Closed underwritten public offering of 11M shares at $9.00/share, gross proceeds $99.0M; net proceeds ~$92.6M.
- Cash and securities $149.1M as of Sept 30, 2023; combined with offering proceeds, cash runway into H2 2026.
- Q3 2023 net loss $18.5M vs $15.9M YoY; R&D expenses $15.4M (up from $11.3M) driven by Phase 2/3 trial costs.
- Positive Phase 2 data for bel-sar in choroidal melanoma: 80% tumor control, 90% visual acuity preservation at 12 months.
- FDA agreed under SPA for Phase 3 CoMpass trial design; first patient dosing expected Q4 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501796/000095017023062074/0000950170-23-062074-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501796/000095017023062074/aura-20231109.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-062074

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer